O'Neill Institute | April 2, 2024
Read the PublicationANTIRETROVIRAL THERAPY (ART) FOR THE TREATMENT OF HIV has allowed for improved health and quality of life, and reduced HIV-related mortality along with reduced transmission of HIV. Since 2012, antiretrovirals also have been available as pre-exposure prophylaxis (PrEP). HIV treatment and prevention regimens, however, have depended on adherence to daily oral pills. While highly effective, some people struggle with daily pill taking. Further, uptake and persistence of oral PrEP has been suboptimal to achieve public health impact. In 2021, the Food and Drug Administration (FDA) approved a longer-acting (LA) injectable form of ART and PrEP. Numerous additional forms of LA products for HIV treatment and PrEP are in the research pipeline.